Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cingal vs triamcinolone hexacetonide for symptomatic relief of knee osteoarthritis
2017-000355-46Phase 3Completed
- Sponsor
- Anika Therapeutics
- Start
- May 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of triamcinolone hexacetonide + hyaluronic acid in knee osteoarthritis (OA) (3 arms), sponsored by Anika Therapeutics. Primary endpoint: Primary: change in WOMAC Pain Score at 26 weeks (Cingal vs TH). Started May 2017; status: completed.
02
Drugs
triamcinolone hexacetonide + hyaluronic acid
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2017-000355-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000355-46.